Basal/HER2 breast carcinomas: Integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)

High rates of inherent primary resistance to the humanized monoclonal antibody trastuzumab (Herceptin) are frequent among HER2 gene-amplified breast carcinomas in both metastatic and adjuvant settings. The clinical efficacy of trastuzumab is highly correlated with its ability to specifically and eff...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Martin-Castillo, Begoña, Oliveras-Ferraros, Cristina, Vazquez-Martin, Alejandro, Cufí, Silvia, Moreno, José Manuel, Corominas-Faja, Bruna, Urruticoechea, Ander, Martín, Ángel G., López-Bonet, Eugeni, Menendez, Javier A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Landes Bioscience 2013
Pynciau:
Perspective
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3575452/
https://ncbi.nlm.nih.gov/pubmed/23255137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cc.23274
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg